Ivy Song

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

Antonella Castagna, Franco Maggiolo, Giovanni Penco et al. · The Journal of Infectious Diseases · 2014 · 329 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

Jan van Lunzen, Franco Maggiolo, José Ramón Arribas et al. · The Lancet Infectious Diseases · 2011 · 298 citations

Pharmacy, Pharmacokinetics, Pharmacotherapy +15

Pharmacokinetics and Safety of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, in Healthy Volunteers

Sherene Min, Ivy Song, Julie Borland et al. · Antimicrobial Agents and Chemotherapy · 2009 · 243 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults

Sherene Min, Louis Sloan, Edwin DeJesus et al. · AIDS · 2011 · 216 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor Dolutegravir Given Twice Daily With Rifampin or Once Daily With Rifabutin

Kelly E. Dooley, Patrick Sayre, Julie Borland et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2012 · 192 citations

Pharmacy, Pharmacokinetics, Pharmacology +17